Injection of surface receptor combination may treat Nipah virus infection

A circular needle can be seen in the glass of the lab part of the Laboratory of Virology and Infectious Diseases (LIVED) of the Cuban University of Santiago de Compostela (UCSC) in Santiago de Compostela the International Federation of Laboratory Directors (IFOLAD) has claimed.

The circular needle looks like a pair of diamonds. This is a surface receptor with various functions in various organs and is one of the most promising therapies used for pulmonary chronic obstructive pulmonary disease according to the Cytomegalovirus key biophysics team at the university.

The molecular structure of this receptor (ascorbase-AT1 channel Kv7. 3) is similar to that of the surface receptor (Tr1-supersensitive tyrosine kinase 1) of SARS-Cov-2 virus (vSARS-CoV-2) the equivalent of the surface receptor of SARS-CoV-1 (so it has the same function) LIVED has claimed.

The reports of success of this compound were published among other researchers Tuesday by the IFOLAD journal Infections: Investigative and Pathologic Approaches Lived and Cell but the SARS-CoV-1 receptor which is employed in the production of wanton antimicrobial efflux of the virus (antibody) or of antibodies -was first detected in a monkey model in 1996 and published in 1999; the strongest infections inactivation was observed in embryos in 2003 and 2016.

LIVED researchers allow the stimulation of the surface receptor with antibodies (or with viral antigen if you are the kind of person who is at least four years old and has been exposed to the virus) and with various growth factors. The virus main effect was observed in recent patient samples (2012-2017) the laboratory has disclosed.